URMC / Research / Clinical Trials / Study Details CGIP19127 / A021602 / Aram HezelResearch Question:How well does cabozantinib S-malate work compared with placebo in treating patients with neuroendocrine tumors that have spread after previous treatment with everolimus?Basic Study Information Purpose:This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth. Location: University of Rochester Medical CenterStudy Reference #: CGIP19127Lead Researcher (Principal Investigator) Lead Researcher: Aram Hezel Study Contact InformationStudy Coordinator: Tina BowdishPhone: +1 585-275-9475Email: tina_bowdish@urmc.rochester.edu Additional Study Details URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search